Belinostat
ALK-Positive Anaplastic Large Cell Lymphoma
Explore 16 assets in ALK-Positive Anaplastic Large Cell Lymphoma →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Corvus Pharmaceuticals, Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
43Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06561048CT.gov Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · ALK-Positive Anaplastic Large Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Belinostat (this asset) | Corvus Pharmaceuticals, Inc. | P3 | B · 58 |
| Etoposide | Mingzhi Zhang | P4 | BB |
| Crizotinib | Mingzhi Zhang | P4 | BB |
| Adriamycin | Huiqiang Huang | P2 | BB |
| Cyclophosphamide | Huiqiang Huang | P2 | BB |
| Dexasone | Huiqiang Huang | P2 | BB |
| Brentuximab Vedotin | New York Medical College | P2 | BB |
| Prednisone | Huiqiang Huang | P2 | BB |
| Soquelitinib | Corvus Pharmaceuticals, Inc. | P3 | B |
+24 more in the ALK-Positive Anaplastic Large Cell Lymphoma cohort
Other indications for Belinostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 65 |
| Diffuse Large B-Cell Lymphoma | — | P2 | B · 63 |
| Burkitt Lymphoma | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Belinostat in ALK-Positive Anaplastic Large Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/belinostat-alk-positive-anaplastic-large-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →